Adam D. Cohen, MD

Adam D. Cohen, MD, said that more data are necessary to help determine how cevostamab can be sequenced with other T-cell–directed therapies.

Adam D. Cohen, MD, says patients with deep responses to cevostamab could stop therapy and stay in remission for years.

Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.

Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.